glp-1 drugs in development Trends the of Receptor Agonists What to Make of the
Description
The combined effect of all three receptor pathways creates something researchers call a synergistic metabolic cascade
3 Risk of pancreatitis has also been identified with taking GLP-1 agonists
FDA approves weight management drug for patients aged 12
10.1136/bmjgh-2024-017177
Weight Regain After Discontinuation Is the Rule, Not the Exception Without addressing: Insulin sensitivity Muscle preservation Nutrient status Lifestyle structure Most patients experience partial or full weight regain after stopping GLP-1 therapy
